US sharemarkets were mixed on Thursday. Restraining prices was a disappointment on a trial of a COVID-19 vaccine. The Financial Times said Gilead Science’s Remdesivir did not improve patients’ conditions in a Chinese trial.
Post Views: 269
US sharemarkets were mixed on Thursday. Restraining prices was a disappointment on a trial of a COVID-19 vaccine. The Financial Times said Gilead Science’s Remdesivir did not improve patients’ conditions in a Chinese trial.